GILD

XNAS

GILEAD SCIENCES INC

Avg. sentiment
0.30neutral

1 news · 90d

7d trend

0 news · vs previous 7d ()

Breakdown
010
Sentiment velocity
+0.000/day

Acceleration —

Sentiment scores computed by AI · Not investment advice.

No price data available for this ticker.

Track $GILD sentiment without checking the page.

Top-discussed tickers and the AI sentiment we read. Not advice.

  • BusinessWire5/21/2026, 1:30:00 PM
    Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

    Gilead Sciences has completed its acquisition of Tubulis GmbH, a private German clinical-stage biotech specializing in next-generation antibody-drug conjugates (ADCs). The deal adds Tubulis' ADC platform and pipeline assets to Gilead's oncology portfolio, enabling more selective tumor-targeted payload delivery. The acquisition was previously announced, making this a closing confirmation rather than a new deal disclosure.

    Sentiment 0.30Relevance 100%